SMT201600320B - Composizione a deposito iniettabile antipsicotica - Google Patents

Composizione a deposito iniettabile antipsicotica

Info

Publication number
SMT201600320B
SMT201600320B SM201600320T SM201600320T SMT201600320B SM T201600320 B SMT201600320 B SM T201600320B SM 201600320 T SM201600320 T SM 201600320T SM 201600320 T SM201600320 T SM 201600320T SM T201600320 B SMT201600320 B SM T201600320B
Authority
SM
San Marino
Prior art keywords
injectionable
synoptic
deposit
composition
synoptic injectionable
Prior art date
Application number
SM201600320T
Other languages
English (en)
Inventor
Ochoa María Teresa Gomez
Aduriz Ibon Gutierro
Original Assignee
Laboratorios Farmacéuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43301889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600320(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Farmacéuticos Rovi S A filed Critical Laboratorios Farmacéuticos Rovi S A
Publication of SMT201600320B publication Critical patent/SMT201600320B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
SM201600320T 2010-05-31 2016-09-15 Composizione a deposito iniettabile antipsicotica SMT201600320B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382154.2A EP2394664B1 (en) 2010-05-31 2010-05-31 Antipsychotic injectable depot composition
PCT/EP2011/059000 WO2011151355A1 (en) 2010-05-31 2011-05-31 Antipsychotic injectable depot composition

Publications (1)

Publication Number Publication Date
SMT201600320B true SMT201600320B (it) 2016-11-10

Family

ID=43301889

Family Applications (2)

Application Number Title Priority Date Filing Date
SM201600321T SMT201600321B (it) 2010-05-31 2016-09-15 Composizione iniettabile a rilascio graduale antipsicotica
SM201600320T SMT201600320B (it) 2010-05-31 2016-09-15 Composizione a deposito iniettabile antipsicotica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM201600321T SMT201600321B (it) 2010-05-31 2016-09-15 Composizione iniettabile a rilascio graduale antipsicotica

Country Status (32)

Country Link
US (2) US10085936B2 (it)
EP (2) EP2394664B1 (it)
JP (1) JP5882993B2 (it)
KR (1) KR101784330B1 (it)
CN (1) CN103002917B (it)
AP (1) AP3524A (it)
AU (1) AU2011260318B2 (it)
BR (1) BR112012030686B1 (it)
CA (1) CA2800111C (it)
CL (1) CL2012003350A1 (it)
CY (2) CY1117969T1 (it)
DK (2) DK2394664T3 (it)
EA (1) EA024155B1 (it)
ES (2) ES2589106T3 (it)
HR (2) HRP20161049T1 (it)
HU (2) HUE029895T2 (it)
IL (1) IL223129A (it)
LT (2) LT2394664T (it)
MA (1) MA34296B1 (it)
ME (1) ME02501B (it)
MX (1) MX338373B (it)
MY (1) MY161930A (it)
NZ (1) NZ604342A (it)
PL (2) PL2394664T3 (it)
PT (2) PT2394664T (it)
RS (1) RS55190B1 (it)
SG (1) SG185775A1 (it)
SI (2) SI2394664T1 (it)
SM (2) SMT201600321B (it)
UA (1) UA108885C2 (it)
WO (1) WO2011151355A1 (it)
ZA (1) ZA201209346B (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
ES2589106T3 (es) 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
PL2529757T3 (pl) * 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
ES2878112T3 (es) * 2011-05-31 2021-11-18 Farm Rovi Lab Sa Formulación de implante de risperidona y/o paliperidona
US9737605B2 (en) 2013-03-11 2017-08-22 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
US10646443B2 (en) 2017-03-20 2020-05-12 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
CN110420212A (zh) * 2019-08-19 2019-11-08 韩自勤 一种用于治疗精神分裂症组合物及其制备方法
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
NZ276088A (en) 1993-11-19 1999-07-29 Janssen Pharmaceutica Nv [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
CA2591581C (en) 1996-12-20 2013-01-29 Alza Corporation Gel composition and methods
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
DE10190041D2 (de) * 2000-01-11 2002-12-05 Roland Bodmeier Implantate, Partikel
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
US8501215B2 (en) * 2002-07-31 2013-08-06 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
HUE025842T2 (en) 2007-02-15 2016-04-28 Tolmar Therapeutics Inc Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers
CA2686137C (en) * 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
CA2687979C (en) * 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
KR101626632B1 (ko) * 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
ES2589106T3 (es) 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
PL2529757T3 (pl) 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
ES2878112T3 (es) 2011-05-31 2021-11-18 Farm Rovi Lab Sa Formulación de implante de risperidona y/o paliperidona

Also Published As

Publication number Publication date
NZ604342A (en) 2014-11-28
LT2394664T (lt) 2016-09-26
AP3524A (en) 2016-01-11
JP5882993B2 (ja) 2016-03-09
RS55190B1 (sr) 2017-01-31
KR101784330B1 (ko) 2017-10-11
EP2575890A1 (en) 2013-04-10
EP2394664B1 (en) 2016-06-01
KR20130118742A (ko) 2013-10-30
MX338373B (es) 2016-04-13
HRP20161100T1 (hr) 2016-11-04
UA108885C2 (uk) 2015-06-25
HUE029056T2 (en) 2017-02-28
EP2394664A1 (en) 2011-12-14
CN103002917B (zh) 2016-04-27
EA201201569A1 (ru) 2013-04-30
CY1117964T1 (el) 2017-05-17
CN103002917A (zh) 2013-03-27
PL2575890T3 (pl) 2016-12-30
SI2394664T1 (sl) 2016-10-28
ES2589106T3 (es) 2016-11-10
US10085936B2 (en) 2018-10-02
US20130171202A1 (en) 2013-07-04
SI2575890T1 (sl) 2016-10-28
WO2011151355A1 (en) 2011-12-08
JP2013528612A (ja) 2013-07-11
SMT201600321B (it) 2016-11-10
BR112012030686A2 (pt) 2020-08-25
ES2592527T3 (es) 2016-11-30
BR112012030686B1 (pt) 2022-11-01
PT2575890T (pt) 2016-09-06
CY1117969T1 (el) 2017-05-17
AU2011260318B2 (en) 2014-11-27
DK2575890T3 (en) 2016-09-12
LT2575890T (lt) 2016-09-26
MX2012013937A (es) 2013-02-11
HRP20161049T1 (hr) 2016-12-30
PL2394664T3 (pl) 2016-12-30
AP2012006626A0 (en) 2012-12-31
DK2394664T3 (en) 2016-09-12
CA2800111A1 (en) 2011-12-08
HUE029895T2 (en) 2017-04-28
CL2012003350A1 (es) 2013-10-18
IL223129A0 (en) 2013-02-03
PT2394664T (pt) 2016-09-06
US10182982B2 (en) 2019-01-22
EA024155B1 (ru) 2016-08-31
CA2800111C (en) 2018-05-22
MA34296B1 (fr) 2013-06-01
SG185775A1 (en) 2013-01-30
IL223129A (en) 2016-02-29
ME02501B (me) 2017-02-20
MY161930A (en) 2017-05-15
US20180221272A1 (en) 2018-08-09
ZA201209346B (en) 2013-08-28
EP2575890B1 (en) 2016-06-01
AU2011260318A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
SMT201600320B (it) Composizione a deposito iniettabile antipsicotica
DK2371923T3 (da) Aflejringshæmmer
BR112012031667A2 (pt) composição
DK2542189T3 (da) Håndprotese
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
BR112013009935C8 (pt) compostos
DK2640893T4 (da) Sammensætninger
BR112013003753A2 (pt) compostos
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2526158T3 (da) Forbedret klæbemiddelsammensætning
DK2686017T3 (da) Oftalmisk sammensætning
DOP2012000224A (es) Compuesto heterociclico
BR112014004395A2 (pt) composição
DK2574309T3 (da) Bøjningsstiv acetabularskål
BR112012032683A2 (pt) composição
CO6801726A2 (es) Compuestos
BR112013033808A2 (pt) composição
DK2649070T3 (da) Triazolpyridinforbindelser
DK2561020T3 (da) Coatingsammensætning
BR112012032980A2 (pt) composição
CO6842023A2 (es) Composición herbicida
BR112014012043A2 (pt) emplastro
BR112012026803A2 (pt) composto
BR112013014966A2 (pt) composto aricíclico contínuo